JP2007505938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505938A5 JP2007505938A5 JP2006527348A JP2006527348A JP2007505938A5 JP 2007505938 A5 JP2007505938 A5 JP 2007505938A5 JP 2006527348 A JP2006527348 A JP 2006527348A JP 2006527348 A JP2006527348 A JP 2006527348A JP 2007505938 A5 JP2007505938 A5 JP 2007505938A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- inhibitors
- kinase
- vegf
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 13
- 229940043355 kinase inhibitor Drugs 0.000 claims 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 3
- 229940122361 Bisphosphonate Drugs 0.000 claims 3
- 102000029749 Microtubule Human genes 0.000 claims 3
- 108091022875 Microtubule Proteins 0.000 claims 3
- 108091008605 VEGF receptors Proteins 0.000 claims 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000003886 aromatase inhibitor Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 150000004663 bisphosphonates Chemical class 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 230000005865 ionizing radiation Effects 0.000 claims 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 3
- 210000004688 microtubule Anatomy 0.000 claims 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical group C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 2
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims 2
- 229940124204 C-kit inhibitor Drugs 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 2
- 108091008606 PDGF receptors Proteins 0.000 claims 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 2
- 229940123690 Raf kinase inhibitor Drugs 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims 2
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 claims 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 claims 1
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 102400000967 Bradykinin Human genes 0.000 claims 1
- 101800004538 Bradykinin Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- 102100024025 Heparanase Human genes 0.000 claims 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims 1
- 229940123038 Integrin antagonist Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
- 229940121856 Somatostatin receptor antagonist Drugs 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000009949 anti-apoptotic pathway Effects 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 230000000719 anti-leukaemic effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229960001442 gonadorelin Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 108010037536 heparanase Proteins 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 230000034512 ubiquitination Effects 0.000 claims 1
- 238000010798 ubiquitination Methods 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 2
- -1 methoxy, ethoxy, isopropyloxy Chemical group 0.000 description 2
- 125000006610 n-decyloxy group Chemical group 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50525003P | 2003-09-23 | 2003-09-23 | |
| PCT/EP2004/010686 WO2005027972A2 (en) | 2003-09-23 | 2004-09-23 | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505938A JP2007505938A (ja) | 2007-03-15 |
| JP2007505938A5 true JP2007505938A5 (enExample) | 2007-11-08 |
Family
ID=34375569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527348A Pending JP2007505938A (ja) | 2003-09-23 | 2004-09-23 | Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080085902A1 (enExample) |
| EP (1) | EP1682181A2 (enExample) |
| JP (1) | JP2007505938A (enExample) |
| KR (1) | KR20060097000A (enExample) |
| CN (1) | CN1856327A (enExample) |
| AU (1) | AU2004273615B2 (enExample) |
| BR (1) | BRPI0414698A (enExample) |
| CA (1) | CA2537991A1 (enExample) |
| CO (1) | CO5680459A2 (enExample) |
| CR (1) | CR8283A (enExample) |
| EA (1) | EA200600495A1 (enExample) |
| EC (1) | ECSP066437A (enExample) |
| IL (1) | IL174214A0 (enExample) |
| MX (1) | MXPA06003163A (enExample) |
| NO (1) | NO20061777L (enExample) |
| WO (1) | WO2005027972A2 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US7874293B2 (en) * | 2003-02-21 | 2011-01-25 | Resmed Limited | Nasal assembly |
| EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| US8029815B2 (en) | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| JP5422120B2 (ja) | 2004-05-27 | 2014-02-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法 |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| EP1796672A1 (en) * | 2004-09-27 | 2007-06-20 | AstraZeneca AB | Cancer combination therapy comprising azd2171 and imatinib |
| ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| DE602006017188D1 (de) * | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| WO2007014335A2 (en) * | 2005-07-27 | 2007-02-01 | The University Of Texas System | Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| EP1942882A2 (en) * | 2005-10-24 | 2008-07-16 | Novartis AG | Combination of histone deacetylase inhibitors and radiation |
| KR101353763B1 (ko) * | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용 |
| CN100441222C (zh) * | 2005-12-09 | 2008-12-10 | 中国科学院广州生物医药与健康研究院 | 化合物ps-341在制备治疗急性髓性白血病药物中的应用 |
| FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| MY149337A (en) | 2006-06-12 | 2013-08-30 | Novartis Ag | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
| WO2008033746A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| US9526707B2 (en) | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
| WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| JP5425180B2 (ja) | 2008-03-27 | 2014-02-26 | ザイモジェネティクス， インコーポレイテッド | ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法 |
| WO2010091234A2 (en) * | 2009-02-06 | 2010-08-12 | The General Hospital Corporation | Methods of treating vascular lesions |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| WO2011040496A1 (ja) * | 2009-09-30 | 2011-04-07 | 株式会社資生堂 | ヘパラナーゼ活性阻害剤 |
| ES2468827T3 (es) | 2010-01-14 | 2014-06-17 | Sanwa Kagaku Kenkyusho Co., Ltd | Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| WO2012105610A1 (ja) | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP6150813B2 (ja) | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| HK1214765A1 (zh) * | 2012-11-08 | 2016-08-05 | Novartis Ag | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| WO2016010886A1 (en) * | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| BR102014023144B1 (pt) * | 2014-09-18 | 2020-12-15 | Universidade De São Paulo - Usp | peptídeos sintéticos ligantes de receptores de vegf e seus usos |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| EP3740210A4 (en) * | 2018-01-19 | 2022-02-16 | Indiana University Research and Technology Corporation | THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US12523663B2 (en) | 2019-06-04 | 2026-01-13 | Inserm (Institut National De La Santé Et De La Rescherche Médicale) | Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| WO2025160930A1 (zh) * | 2024-02-02 | 2025-08-07 | 基亚生物科技股份有限公司 | 母帕司汀(Muparfostat)治疗胰腺癌的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2002066479A1 (en) * | 2001-02-23 | 2002-08-29 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindole derivatives |
| AU2002342678B2 (en) * | 2001-09-12 | 2006-08-24 | Novartis Ag | Use of 4-pyridylmethylphthalazines for cancer treatment |
| NZ552335A (en) * | 2001-10-25 | 2008-11-28 | Novartis Ag | Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
-
2004
- 2004-09-23 EA EA200600495A patent/EA200600495A1/ru unknown
- 2004-09-23 KR KR1020067005644A patent/KR20060097000A/ko not_active Withdrawn
- 2004-09-23 MX MXPA06003163A patent/MXPA06003163A/es not_active Application Discontinuation
- 2004-09-23 CN CNA2004800275441A patent/CN1856327A/zh active Pending
- 2004-09-23 CA CA002537991A patent/CA2537991A1/en not_active Abandoned
- 2004-09-23 US US10/573,163 patent/US20080085902A1/en not_active Abandoned
- 2004-09-23 BR BRPI0414698-0A patent/BRPI0414698A/pt not_active IP Right Cessation
- 2004-09-23 AU AU2004273615A patent/AU2004273615B2/en not_active Ceased
- 2004-09-23 JP JP2006527348A patent/JP2007505938A/ja active Pending
- 2004-09-23 WO PCT/EP2004/010686 patent/WO2005027972A2/en not_active Ceased
- 2004-09-23 EP EP04765542A patent/EP1682181A2/en not_active Withdrawn
-
2006
- 2006-03-09 IL IL174214A patent/IL174214A0/en unknown
- 2006-03-14 CR CR8283A patent/CR8283A/es not_active Application Discontinuation
- 2006-03-17 EC EC2006006437A patent/ECSP066437A/es unknown
- 2006-03-30 CO CO06031465A patent/CO5680459A2/es not_active Application Discontinuation
- 2006-04-21 NO NO20061777A patent/NO20061777L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12336993B2 (en) | Therapeutic benefit of suboptimally administered chemical compounds | |
| Eckhardt | Recent progress in the development of anticancer agents | |
| JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| US20220233530A9 (en) | Intermittent dosing of mdm2 inhibitor | |
| EA200600495A1 (ru) | Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом | |
| EP1492567A1 (en) | Formulations and methods of using nitric oxide mimetics in cancer treatment | |
| JP2020172504A (ja) | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 | |
| Ory et al. | Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development, and synergistically acts with zoledronic acid to delay osteosarcoma progression | |
| US10350207B2 (en) | PAC-1 combination therapy | |
| WO2009002553A1 (en) | Methods of treating multiple myeloma and resistant cancers | |
| JP6526789B2 (ja) | 組み合わせ療法 | |
| JP2019514864A (ja) | 肝癌の治療方法 | |
| US11850234B2 (en) | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | |
| JP2014512362A5 (enExample) | ||
| US20240269136A1 (en) | Egfr inhibitor and perk activator in combination therapy and their use for treating cancer | |
| TWI798994B (zh) | 醫藥組合物治療肺癌之用途 | |
| RU2011113815A (ru) | Применение средств, связывающих edg-рецептор, в лечении ракового заболевания | |
| RU2776995C2 (ru) | Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью | |
| HK40122790A (en) | Methods and uses for treating cancer | |
| US20060167006A1 (en) | Method of treatment |